Paradigm Biocapital Advisors LP Has $38.50 Million Stock Holdings in Immatics (NASDAQ:IMTX)

Paradigm Biocapital Advisors LP increased its position in shares of Immatics (NASDAQ:IMTX) by 38.7% during the 4th quarter, Holdings Channel reports. The fund owned 5,414,409 shares of the company’s stock after buying an additional 1,509,547 shares during the quarter. Immatics accounts for about 1.3% of Paradigm Biocapital Advisors LP’s investment portfolio, making the stock its 18th biggest holding. Paradigm Biocapital Advisors LP’s holdings in Immatics were worth $38,496,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IMTX. T. Rowe Price Investment Management Inc. raised its holdings in Immatics by 43.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company’s stock worth $75,400,000 after purchasing an additional 3,225,141 shares during the period. Braidwell LP increased its position in shares of Immatics by 112.7% in the 4th quarter. Braidwell LP now owns 3,503,965 shares of the company’s stock valued at $24,913,000 after buying an additional 1,856,400 shares in the last quarter. Orbimed Advisors LLC lifted its holdings in Immatics by 53.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,087,462 shares of the company’s stock worth $21,952,000 after acquiring an additional 1,081,081 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in Immatics by 12.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company’s stock worth $51,731,000 after acquiring an additional 832,432 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Immatics by 7.6% in the fourth quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company’s stock valued at $74,071,000 after acquiring an additional 736,709 shares during the period. Institutional investors and hedge funds own 64.41% of the company’s stock.

Immatics Trading Down 4.8%

Shares of IMTX opened at $4.34 on Wednesday. The firm has a fifty day simple moving average of $4.47 and a 200 day simple moving average of $5.94. The stock has a market capitalization of $527.53 million, a price-to-earnings ratio of -6.58 and a beta of 0.87. Immatics has a 12 month low of $3.30 and a 12 month high of $13.77.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Thursday, March 27th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.51. The company had revenue of $15.67 million during the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. As a group, research analysts predict that Immatics will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a research report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $16.67.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.